Real-life safety and effectiveness outcomes of teriflunomide in patients with relapsing–remitting multiple sclerosis: The TERICAM study

Real-life safety and effectiveness outcomes of teriflunomide in patients with relapsing–remitting multiple sclerosis: The TERICAM study

Introduction and objective: Teriflunomide is an oral immunomodulatory agent approved for the treatment of relapsing–remitting multiple sclerosis (RRMS). We examined teriflunomide outcomes in patients with RRMS under clinical practice conditions in Spain. Material and methods: Non-interventional, ret...

Full description

Bibliographic Details
Main Authors: M.L. Martínez-Ginés, J.M. García-Domínguez, J.P. Cuello, V. Meca-Lallana, C. Aguirre, L. Costa-Frossard, E. Monreal, S. Sainz de la Maza, P. Salgado-Cámara, A. Labiano-Fontcuberta, L. Fernández-Cabredo, Y. Aladro-Benito, L.B. Canelo, O.Sánchez-del Valle, M.R. Blasco, J. Sabin-Muñoz, A.B. Caminero-Rodríguez, J. Gracia-Gil, E. Fernandez-Diaz, A. Mendoza-Rodríguez, M. Gómez-Moreno, A. Orviz-García, I. Moreno-Torres, L.I. Casanova-Peño, A. Lozano-Ros
Format: Article
Language:English
Published: Elsevier 2023-10-01
Series:Neurology Perspectives
Subjects:
Teriflunomida
evidencia en el mundo real
esclerosis múltiple
esclerosis múltiple remitente-recurrente
tratamiento oral modificador de la enfermedad
TME
Online Access:http://www.sciencedirect.com/science/article/pii/S266704962300025X

Internet

http://www.sciencedirect.com/science/article/pii/S266704962300025X

Similar Items